Six Month Polypill Therapy Improves Lipid Profile in Patients with Previous Acute Myocardial Infarction: The Heart-Mex Study

Méndez-García, Lucía A.; González-Chávez, Antonio; Trejo-Millán, Fernanda; Navarrete-Zarco, Héctor Ulises; Carrero-Aguirre, Miguel; Meléndez, Guillermo; Chávez, Antonio González; Escobedo, Galileo

doi:10.1016/j.arcmed.2019.08.002

Cited by 12 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The decrease in TC and LDL–c parameters observed after one year of treatment with the CNIC-polypill was within the same range as previous randomized controlled trials (RCT) that assessed patients with CVD and patients without previous event [7] , [8] . Expressed as a percentage of change, we observed a reduction of 23% in TC levels and 29% in TG levels, which is in line with those of a recent study also conducted in Mexico that included patients in secondary prevention [24] . However, the percentage LDL–c reduction in our study was 14%, while in the Mendez-Garcia et al study it was 40% [24] .…”

Section: Discussionsupporting

confidence: 91%

“…Expressed as a percentage of change, we observed a reduction of 23% in TC levels and 29% in TG levels, which is in line with those of a recent study also conducted in Mexico that included patients in secondary prevention [24] . However, the percentage LDL–c reduction in our study was 14%, while in the Mendez-Garcia et al study it was 40% [24] . The smaller decrease in LDL–c levels in our study could be attributable to higher mean pre-treatment LDL–c values in their case (135.8 mg/dL vs. 129.6 mg/dL in ours).…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

The CNIC-polypill improves atherogenic dyslipidemia markers in patients at high risk or with cardiovascular disease: Results from a real-world setting in Mexico

Gómez-Álvarez

Verdejo

Ocampo

et al. 2020

IJC Heart & Vasculature

View full text Add to dashboard Cite

Background In many patients, the risk of cardiovascular (CV) events persists despite statin treatment and attaining target LDL–c levels. This residual risk is in part attributed to atherogenic dyslipidemia (AD). We studied the clinical effectiveness of the CNIC-polypill in improving the lipid profile, and lipid ratios and indices indicative of AD that are more accurate in predicting lipid-related CV risk. Methods Post-hoc analysis of a multicenter, observational, non-comparative, prospective registry in 533 patients in Mexico. We evaluated blood lipids at baseline (usual care) and after 12 months of treatment with the CNIC-polypill (Sincronium®), including total cholesterol (TC), triglycerides (TG), cholesterol low-density lipoproteins (LDL–c), cholesterol high-density lipoproteins (HDL–c), and cholesterol non-high-density lipoproteins (non-HDL–c). We also calculated and compared AD-related lipid ratios and indices, including remnant cholesterol (RC), Castelli's risk index-I (CRI–I), atherogenic index (AI), atherogenic coefficient (AC), a surrogate of insulin resistance (IRS), atherogenic index of plasma (AIP), and lipoprotein combined index (LCI). Results At 1 year of treatment, there was a significant reduction in the levels of TC (−22.6%), TG (−29.2%), LDL–c (−13.8%), and non-HDL–c (−29.2%) (all p < 0.001). The likelihood that patients attained their corresponding target LDL–c and TG levels was almost three-fold and seven-fold higher, respectively ( p < 0.001). The values of the AD-related ratios RC, CRI–I, AI, AC, AIP, and LCI were all significantly lower ( p < 0.001) after one year of treatment. Conclusions In patients with or at high risk of CVD, one-year treatment with the CNIC-polypill significantly lowered lipid ratios indicative of AD compared to baseline.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 91%

The CNIC-polypill improves atherogenic dyslipidemia markers in patients at high risk or with cardiovascular disease: Results from a real-world setting in Mexico

Gómez-Álvarez

Verdejo

Ocampo

et al. 2020

IJC Heart & Vasculature

View full text Add to dashboard Cite

show abstract

“…Also, the likelihood that patients attained their corresponding target LDL-Chol and triglyceride levels was almost three-fold and seven-fold higher, respectively, as compared with the prediction from pre-treatment usual care. Of note, the decrease in LDL was smaller than that observed in a previous study of exclusive secondary prevention in a Mexican population [12] . One potential explanation for this difference could reside into the higher LDL Chol values included in the later study.…”

contrasting

confidence: 77%

Polypill revisited – Unity in diversity

Dan

Dobrev

2020

IJC Heart & Vasculature

View full text Add to dashboard Cite

“…It could be argued that higher satisfaction would be indirectly related with a higher degree of treatment adherence, which may result in a better CV risk factors control. In fact, recent data from two different observational studies in a real-life clinical settings in Mexico [18,19] shed some light into this hypothesis, showing that patients treated with a version of the CNIC polypill containing simvastatin instead of atorvastatin improved their blood pressure and lipid levels, and showed a significant reduction Framingham risk score compared with their previous treatment.…”

Section: Discussionmentioning

confidence: 99%

Evaluating patients' satisfaction and preferences with a secondary prevention cardiovascular polypill: the Aurora Study

et al. 2021

View full text Add to dashboard Cite

Aim: To evaluate the satisfaction, preferences and adherence of patients in secondary cardiovascular prevention treated with the CNIC cardiovascular polypill compared with patients treated with the separate monocomponents. Methods: Observational, cross-sectional and multicenter study. Satisfaction was evaluated by the Treatment Satisfaction Questionnaire for Medication 9 items, adherence by the Morisky-Green questionnaire and ad-hoc questions were asked regarding patient preferences. Results: Polypill patients reported higher satisfaction than patients treated with the monocomponents (77.3 vs 71.2%, p < 0.0001). 72.8% of patients treated with the monocomponents would prefer to change to the polypill. Patients treated with the polypill had significantly higher adherence than patients treated with the monocomponents (57.7 vs 41.1%) (p = 0.0027). Conclusion: Polypill patients show higher satisfaction and better adherence. Most patients receiving the monocomponents would prefer a polypill regime.

show abstract

Six Month Polypill Therapy Improves Lipid Profile in Patients with Previous Acute Myocardial Infarction: The Heart-Mex Study

Cited by 12 publications

References 31 publications

The CNIC-polypill improves atherogenic dyslipidemia markers in patients at high risk or with cardiovascular disease: Results from a real-world setting in Mexico

The CNIC-polypill improves atherogenic dyslipidemia markers in patients at high risk or with cardiovascular disease: Results from a real-world setting in Mexico

Polypill revisited – Unity in diversity

Evaluating patients' satisfaction and preferences with a secondary prevention cardiovascular polypill: the Aurora Study

Contact Info

Product

Resources

About